Charles Schwab Investment Management Inc. Sells 5,210 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Charles Schwab Investment Management Inc. trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 747,291 shares of the company’s stock after selling 5,210 shares during the period. Charles Schwab Investment Management Inc. owned about 0.74% of Neurocrine Biosciences worth $86,103,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Massachusetts Financial Services Co. MA lifted its holdings in shares of Neurocrine Biosciences by 4.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 163,054 shares of the company’s stock valued at $18,787,000 after purchasing an additional 7,069 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in Neurocrine Biosciences in the third quarter valued at approximately $1,001,000. Intech Investment Management LLC boosted its holdings in shares of Neurocrine Biosciences by 49.3% in the third quarter. Intech Investment Management LLC now owns 102,595 shares of the company’s stock valued at $11,821,000 after buying an additional 33,897 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Neurocrine Biosciences by 4.7% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company’s stock worth $94,478,000 after acquiring an additional 37,098 shares in the last quarter. Finally, Grandfield & Dodd LLC raised its holdings in shares of Neurocrine Biosciences by 1.8% during the third quarter. Grandfield & Dodd LLC now owns 15,821 shares of the company’s stock worth $1,823,000 after acquiring an additional 280 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Stock Down 1.0 %

Shares of NBIX stock opened at $126.59 on Thursday. Neurocrine Biosciences, Inc. has a 12-month low of $110.81 and a 12-month high of $157.98. The company has a market capitalization of $12.82 billion, a PE ratio of 33.94 and a beta of 0.35. The firm has a 50 day moving average price of $118.97 and a two-hundred day moving average price of $131.71.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on NBIX shares. Royal Bank of Canada reduced their target price on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $131.00 to $159.00 in a report on Thursday, August 29th. HC Wainwright restated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Finally, Citigroup boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.